EUVIMEDEUVIMED entdecken
Crossref

Bioengineered Artificial Extracellular Vesicles Presenting PD-L1 and Gal-9 Ameliorate New-Onset Type 1 Diabetes

Zhaoxin Yang, Zhirang Zhang, Liyan Li, Zhangyan Jing, Yumeng Ma, Tianyu Lan, Yuan Li, Zhongda Lin, Wenli Fang, Jinxie Zhang, Jinling Zhang, Xin Liang und 3 weitere

Diabetes · 2024

DOI: 10.2337/db23-0987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Zhaoxin Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen Uni…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Extracellular Vesicles, B7-H1 Antigen, Galectins. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: the Natural Science Foundation of Guangdong Province, Doctoral personnel scientific research start-up Fund project of Guangdong Medical University, the Health system scientific research project of Shenzhen Guangming District Science and innovation Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An important factor in the development of type 1 diabetes (T1D) is the deficiency of inhibitory immune checkpoint ligands, specifically programmed cell death ligand 1 (PD-L1) and galectin-9 (Gal-9), in β-cells. Therefore, modulation of pancreas-infiltrated T lymphocytes by exogenous PD-L1 or Gal-9 is an ideal approach for treating new-onset T1D. We genetically engineered macrophage cells to generate artificial extracellular vesicles (aEVs) overexpressing PD-L1 and Gal-9, which could restrict islet autoreactive T lymphocytes and protect β-cells from destruction. Intriguingly, overexpression of Gal-9 stimulated macrophage polarization to the M2 phenotype with immunosuppressive attributes. Alternatively, both PD-L1– and Gal-9–presenting aEVs (PD-L1–Gal-9 aEVs) favorably adhered to T cells via the interaction of programmed cell death protein 1/PD-L1 or T-cell immunoglobulin mucin 3/Gal-9. Moreover, PD-L1–Gal-9 aEVs prominently promoted effector T-cell apoptosis and splenic regulatory T (Treg) cell formation in vitro. Notably, PD-L1–Gal-9 aEVs efficaciously reversed new-onset hyperglycemia in NOD mice, prevented T1D progression, and decreased the proportion and activation of CD4+ and CD8+ T cells infiltrating the pancreas, which together contributed to the preservation of residual β-cell survival and mitigation of hyperglycemia. Article Highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Extracellular VesiclesB7-H1 AntigenGalectinsMice, Inbred NODAnimalsMiceInsulin-Secreting CellsMacrophagesT-Lymphocytes, RegulatoryBioengineeringFemale

Substanzen

B7-H1 AntigenGalectinsCd274 protein, mousegalectin 9, mouse

Autor:innen und Institutionen

  • Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.
  • Department of Gynaecology, Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
  • Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Key Laboratory of Stem Cell and Regenerative Tissue Engineering, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong,…
  • Center for Medical Experiments (CME), Benqing Laboratory, Guangming District People's Hospital, Shenzhen, Guangdong, China.

ORCID-Profile: Xudong Zhang

Förderung

  • the Natural Science Foundation of Guangdong Province
  • Doctoral personnel scientific research start-up Fund project of Guangdong Medical University
  • the Health system scientific research project of Shenzhen Guangming District Science and innovation Bureau
  • Shenzhen Science and Technology Program
  • Special fund for economic development of ShenZhen Guangming District
  • Guangdong Basic and Applied Basic Research Foundation
  • University of Chinese Academy of Sciences-Shenzhen Hospital Research Funding
  • The National Natural Science Foundation of China

Zitieren

APA

Yang, Z., Zhang, Z., Li, L., Jing, Z., Ma, Y., Lan, T., Li, Y., Lin, Z., Fang, W., Zhang, J., Zhang, J., Liang, X., Wu, B., Zheng, Y., & Zhang, X. (2024). Bioengineered Artificial Extracellular Vesicles Presenting PD-L1 and Gal-9 Ameliorate New-Onset Type 1 Diabetes. Diabetes. https://doi.org/10.2337/db23-0987

Vancouver

Yang Z, Zhang Z, Li L, Jing Z, Ma Y, Lan T, et al. Bioengineered Artificial Extracellular Vesicles Presenting PD-L1 and Gal-9 Ameliorate New-Onset Type 1 Diabetes. Diabetes. 2024. doi:10.2337/db23-0987

BibTeX
@article{Yang2024,
  author = {Yang, Zhaoxin and Zhang, Zhirang and Li, Liyan and Jing, Zhangyan and Ma, Yumeng and Lan, Tianyu and Li, Yuan and Lin, Zhongda and Fang, Wenli and Zhang, Jinxie and Zhang, Jinling and Liang, Xin and Wu, Benqing and Zheng, Yi and Zhang, Xudong},
  title = {Bioengineered Artificial Extracellular Vesicles Presenting PD-L1 and Gal-9 Ameliorate New-Onset Type 1 Diabetes},
  journal = {Diabetes},
  year = {2024},
  doi = {10.2337/db23-0987}
}
Kostenlos starten →